Oncology in 2012: from personalized medicine to precision medicine
نویسندگان
چکیده
منابع مشابه
CROSSING THE WAY OF PRECISION MEDICINE APPROACH IN PERSONALIZED MEDICINE RESEARCH CENTER: A SYSTEMATIC REVIEW
Background: Precision medicine is a new approach in the field of medical sciences that utilizes the genetic characteristics of each patient along with clinical information to guide decisions related to diagnosis and early treatment of diseases. The Personalized Medicine Research Center, as the only center approved by the Ministry of Health, is working on precision medicine context and producing...
متن کاملPrecision medicine in pediatric oncology
PURPOSE OF REVIEW The current review describes recent advances and unique challenges in precision medicine for pediatric cancers and highlights clinical trials assessing the clinical impact of targeted therapy matched to molecular alterations identified by tumor profiling. RECENT FINDINGS Multiple prospective clinical sequencing studies in pediatric oncology have been reported in the last 2 y...
متن کاملFrom Patient-Specific Mathematical Neuro-Oncology to Precision Medicine
Gliomas are notoriously aggressive, malignant brain tumors that have variable response to treatment. These patients often have poor prognosis, informed primarily by histopathology. Mathematical neuro-oncology (MNO) is a young and burgeoning field that leverages mathematical models to predict and quantify response to therapies. These mathematical models can form the basis of modern "precision me...
متن کاملPersonalized Medicine in Oncology in Canada
of a National Genetics Advisory Panel that would review research and provide recommendations on tests for funding or reimbursement, guidelines, service delivery models, laboratory quality assurance, education, and communication. More has to be known about the current state of personalized cancer medicine in Canada, and strategies have to be developed to inform and improve understanding and appr...
متن کاملFrom Evidence-based Medicine to Personalized Medicine
elderly population. The subgroup analysis of the NSABP C-07 trial showed a trend towards better disease-free survival in patients younger than age 70 (hazard ratio, 0.80; 95% confidence interval, 0.68 to 0.95; P = 0.013), but no positive effect was evident in older patients with the addition of oxaliplatin to the FL regimen [10]. Even the NCCN guideline recommended that the oxaliplatinbased reg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Targeted Oncology
سال: 2012
ISSN: 1776-2596,1776-260X
DOI: 10.1007/s11523-012-0238-5